Description of the active substance:
This information is a reference and it is not enough that the drug has been prescribed by a doctor ..
PHARMACHOLOGIC EFFECT
Antibiotic group of carbapenems. More stable with respect to dehydropeptidase I than imipenem. Has a bactericidal effect due to a violation of the synthesis of the bacterial cell wall. Has an affinity for proteins that bind penicillin (PBPs). It is active against most aerobic and anaerobic gram-positive and gram-negative bacteria.
To meropenem are stable Xanthomonas maltophilia, Enterococcus faecium, methicillin-resistant strains of Staphylococcus spp.
Resistant to the action of? -lactamases.
PHARMACOKINETICS
After IV or IM, it penetrates well into most tissues and body fluids (including cerebrospinal fluid in meningitis patients). Metabolized with the formation of one inactive metabolite. T 1/2 with iv introduction is 1 hour, with a / m introduction - 1.5 hours.
INDICATIONS
For intravenous administration: treatment of infectious-inflammatory diseases of severe course caused by one or more meropenem-sensitive pathogens: pneumonia, including hospital pneumonia; urinary tract infection, abdominal cavity, pelvic organs (including endometritis), skin and soft tissues, meningitis, septicemia; suspicion of a bacterial infection with febrile episodes on the background of neutropenia (empirical treatment).
For the / m introduction: exacerbation of chronic bacterial bronchitis, uncomplicated urinary tract infections.
DOSING MODE
In / in adults, a single dose varies from 500 mg to 2 g, the frequency of administration and duration of treatment are set individually, depending on the indications and severity of the course of the disease. Children with body weight less than 50 kg - 10-12 mg / kg every 8 hours; in children with a body weight of more than 50 kg, doses intended for adults are used.
In / m adults - 500 mg every 8 hours, elderly patients - 500 mg every 12 hours.
SIDE EFFECT
On the part of the digestive system: abdominal pain, nausea, vomiting, diarrhea, reversible increase in bilirubin, transaminase, alkaline phosphatase and LDH.
From the coagulation system: reversible thrombocytopenia, eosinophilia, neutropenia.
Allergic reactions: itching, rash, hives.
From the nervous system: headache, paresthesia.
Effects due to the chemotherapeutic effect: candidiasis of the oral cavity, vaginal candidiasis, pseudomembranous colitis.
Local reactions: inflammation, thrombophlebitis, pain at the injection site.
Other: in some cases positive direct or indirect Coombs test.
CONTRAINDICATIONS
Hypersensitivity to meropenem and other drugs of the carbapenem group.
PREGNANCY AND LACTATION
In pregnancy and during lactation (breastfeeding), application is only possible in cases where the expected benefit of therapy for the mother exceeds the possible risk to the fetus or child.
In experimental studies, it is shown that meropenem is excreted in breast milk.
APPLICATION FOR FUNCTIONS OF THE LIVER
In case of violations of the kidney function, a correction of the dosing regimen is required depending on the CK values.
APPLICATION FOR VIOLATIONS OF THE FUNCTION OF KIDNEYS
C carefully prescribed meropenem for liver disease - treatment should be carried out under the control of the level of transaminases and bilirubin.
APPLICATION FOR CHILDREN
It is not recommended to use in children under 3 months.
SPECIAL INSTRUCTIONS
C carefully prescribed meropenem for liver disease, with diseases of the lower respiratory tract caused by Pseudomonas aeruginosa.
In case of violations of the kidney function, a correction of the dosing regimen is required depending on the CK values. With liver diseases treatment should be carried out under the control of the level of transaminases and bilirubin.
At the instructions in the anamnesis on reactions of hypersensitivity to penicillins, carbapenems or other beta-lactam antibiotics, the development of hypersensitivity reactions to meropenem is possible. As with the use of other antibiotics, against the background of treatment meropenem should be borne in mind the likelihood of developing pseudomembranous colitis.
With care use meropenem in the combination therapy with drugs that have a nephrotoxic effect.
It is not recommended to use in children under 3 months.
DRUG INTERACTION
Probenecid competes with meropenem for active tubular secretion and, thus, inhibits renal excretion of meropenem, causing an increase in its T 1/2 and plasma concentration (simultaneous use is not recommended).
